I'll research REGN before writing the preview. Let me start by gathering recent filings, transcripts, and news.Let me read the most recent quarter's transcript and release, and gather recent news.Let me get recent news and stock price context.The stock dropped sharply around May 18, 2026 (from ~$698 to ~$630). Let me investigate what happened and find Q2 catalysts.The July 6 8-K about a Q2 R&D charge is important. Let me read it and confirm the fianlimab melanoma failure details.Let me pull the year-ago Q2 2025 release for YoY comparison baselines.I have what I need. Here's the earnings preview.
Regeneron heads into this print with something to prove. The stock closed at ~$696 on July 29, down roughly 10% year-to-date (from ~$776 in early January), and that understates the volatility — shares troughed near $600 in early June, a ~23% drawdown, before staging a ~16% recovery into the print (including a notable two-day pop on July 28–29). The overhang is a combination of an eroding EYLEA base business, a high-profile pipeline failure, and manufacturing/pricing noise. This quarter is about whether the growth engine (Dupixent, EYLEA HD, Libtayo) is durable enough to offset those headwinds while the market waits on second-half catalysts.
The comparison is optically tricky: last year's 2Q25 non-GAAP EPS of $12.89 was flattered by an unusually low 8.3% tax rate (an IRS audit settlement released reserves). So a headline "EPS down big" is likely a comp artifact, not a fundamentals story — focus on revenue lines and profit-share dynamics instead.
The single biggest event since the last print: on May 18, 2026, Regeneron disclosed that its Phase 3 first-line metastatic melanoma trial of fianlimab (LAG-3) + Libtayo missed its primary endpoint, and the stock fell ~11% in a day. This matters because: - Management had already walked away from fianlimab in first-line NSCLC (Phase 2 didn't support Phase 3), so melanoma was the lead indication. - Still outstanding: the adjuvant melanoma study continues, with a second interim (and possible final) analysis in 2H26. - Expect pointed Q&A on read-through to the broader LAG-3/oncology strategy. Recall that on the 1Q call, an analyst (Risinger) bluntly noted the Street "lacks confidence" that REGN's pipeline candidates can move the needle commercially — fianlimab's miss hardens that skepticism. Watch how Len/George pivot the oncology narrative toward Lynozyfic (myeloma), odronextamab (follicular lymphoma), and the Telix radiopharma collaboration.
This is the swing factor for the quarter's product-sales line. - EYLEA HD (the growth driver): grew 52% YoY to $468M in the U.S. in 1Q, with physician unit demand +10% sequentially despite seasonality. Management guided to ~10% sequential unit-demand growth again in 2Q. HD now makes up ~half of U.S. retina net sales. - EYLEA (the melting ice cube): 1Q U.S. sales fell 36% YoY; management guided to mid- to high-teens demand decline in 2Q ahead of additional biosimilars in 2H26, plus a ~$20M inventory drawdown headwind. (Note: the Samsung Bioepis 2mg biosimilar is enjoined until January 2027 per a February settlement, but other biosimilars loom.) - The pre-filled syringe (PFS) catalyst: REGN resubmitted the PFS application at Catalent Indiana after a site re-inspection, and a second contract-manufacturer application remains pending (FDA missed the April PDUFA). Management said it expects a decision on one or both applications during 2Q — so an approval could land in the release or on the call, and would be a genuine positive for HD's competitive positioning.
Dupixent remains the anchor: ~$4.9B global net sales in 1Q (+33%), tracking toward a ~$20B annual run-rate with continued label expansion (AFRS, pediatric CSU, bullous pemphigoid). Two things to watch: - The Sanofi profit-share step-up. Management said the Sanofi development balance would be fully repaid by the end of 2Q, after which REGN's collaboration revenue steps up to reflect its full share of collaboration profits starting in 3Q. Confirmation of this timing is a tangible tailwind into the back half. - Next-gen/lifecycle strategy. With Dupixent IP eventually expiring, watch for updates on the long-acting IL-13 antibody (first-in-human expected mid-2026) and any commentary on collaborating with Sanofi's new CEO (Belén Garijo took over; Paul Hudson departed).
| Metric | 1Q26 actual | 2Q25 (year-ago) | What to watch in 2Q26 |
|---|---|---|---|
| Total revenue | $3.6B (+19%) | $3.68B | Sanofi profit share + HD/Libtayo growth vs. EYLEA erosion |
| Dupixent global | $4.88B (+33%) | $4.34B | Continued ~30%+ growth; run-rate toward $20B |
| EYLEA HD U.S. | $468M (+52%) | $393M | ~10% sequential unit demand growth guided |
| EYLEA U.S. | $473M (−36%) | $754M | Mid/high-teens demand decline + ~$20M inventory drag |
| Libtayo global | $438M (+54%) | $377M | Adjuvant CSCC ramp; note 1Q had a favorable inventory comp |
| Non-GAAP EPS | $9.47 (+15%) | $12.89* | *Prior-yr tax-rate flattered; new ~$1.00 IPR&D hit this qtr |
Known 2Q items already flagged: - ~$127M pre-tax acquired IPR&D charge (from up-front/opt-in deal payments), a ~$1.00 hit to both GAAP and non-GAAP diluted EPS (disclosed in a July 6 8-K). This is real and pre-announced — don't confuse it with an operational miss. - Limerick, Ireland manufacturing interruption: temporary bulk-production halt hit GAAP gross margin; full-year GAAP GM guidance was cut to 77–78% (from 79–80%), with continued 2Q pressure expected before production normalizes by quarter-end. Management stresses no product-availability impact.
Given the in-quarter fundamentals are relatively "known," the call may hinge on the second-half catalyst path: - Garetosmab (FOP): FDA decision (PDUFA) in August 2026 — near-term, first-in-class rare-disease opportunity. - Cemdisiran (C5 siRNA) in generalized myasthenia gravis: NDA filed with a priority review voucher; FDA decision expected 4Q26. This is the lead asset in REGN's "pipeline-in-a-franchise" complement story. - PNH combo (cemdisiran + pozelimab): registrational cohort data late 4Q26. - Geographic atrophy (C5): interim exploratory data 4Q26 to inform pivotal strategy. - Obesity: olatorepatide (GLP-1/GIP, in-licensed from Hansoh) Phase 2 enrolling; two global Phase 3 programs expected to start later in 2026; plus the differentiated olatorepatide + Praluent combo thesis (weight loss plus ~50%+ LDL lowering) that management is clearly excited about. - Factor XI anticoagulation: a large multi-study Phase 3 program (11 trials referenced) — long-dated but a potential mega-opportunity.
The bar is arguably reset lower after the fianlimab miss and the first-half drawdown, but the buy-side debate is unchanged: is Dupixent + EYLEA HD + Libtayo growth durable enough to carry the P&L through EYLEA biosimilar erosion until the next pipeline wave (complement, obesity, Factor XI) arrives? For this specific print, the operational tells are: (1) EYLEA HD hitting the ~10% sequential demand bogey, (2) the pace of EYLEA erosion and any biosimilar timing update, (3) a possible PFS approval, and (4) confirmation that the Sanofi profit-share step-up begins in 3Q. Headline EPS will look noisy — the ~$1.00 IPR&D charge and the tough tax-rate comp mean the market should look through it to the revenue mix and 2H catalyst commentary.
Note: I was unable to retrieve published sell-side consensus estimates for the quarter through the available tools, so this preview frames expectations around company guidance and the year-ago base rather than a specific consensus EPS/revenue number.